600211 西藏药业
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)17.46425.20013.1108.02616.680
总资产报酬率 ROA (%)12.55918.4399.3606.19414.640
投入资产回报率 ROIC (%)14.82021.71111.0287.23016.625

边际利润分析
销售毛利率 (%)95.69595.05294.25889.56285.801
营业利润率 (%)43.18728.68518.18912.00834.383
息税前利润/营业总收入 (%)40.86227.58118.30712.23233.266
净利润/营业总收入 (%)38.77425.85114.6919.96130.636

收益指标分析
经营活动净收益/利润总额(%)84.212119.799160.019222.55889.722
价值变动净收益/利润总额(%)0.477-18.937-1.54157.4740.202
营业外收支净额/利润总额(%)-0.210-0.100-0.272-0.765-0.383

偿债能力分析
流动比率 (X)2.7962.8732.6431.9664.056
速动比率 (X)2.7092.7792.5451.8433.844
资产负债率 (%)28.31126.45826.07230.4430.121
带息债务/全部投入资本 (%)15.98412.56513.21015.9850.128
股东权益/带息债务 (%)521.257689.815647.811516.18077,614.078
股东权益/负债合计 (%)251.007275.561281.766227.218723.810
利息保障倍数 (X)-18.293-25.643108.98638.756-33.728

营运能力分析
应收账款周转天数 (天)72.38763.03864.69167.69283.922
存货周转天数 (天)310.947245.342291.134167.867134.294